Search Results

You are looking at 131 - 140 of 2,864 items for :

  • Refine by Access: All x
Clear All
Full access

SupportScreen: A Model for Improving Patient Outcomes

Matthew Loscalzo, Karen Clark, Jeff Dillehunt, Redmond Rinehart, Rex Strowbridge, and Daniel Smith

authors have taken this process a step further by automating biopsychosocial screening through the use of touch-screen technology. 12 SupportScreen Improved Patient Outcomes “At Your Fingertips” The authors' team developed a new touch screen

Full access

Patient-Reported Outcomes in Multiple Myeloma

Stephanie J. Lee

multiple myeloma . N Engl J Med 2003 ; 348 : 1875 – 1883 . 6 American Society of Clinical Oncology . Outcomes of cancer treatment for technology assessment and cancer treatment guidelines . J Clin Oncol 1996 ; 14 : 671 – 679 . 7

Full access

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

focused on receipt of locoregional treatment, compared with others with N0M0 disease, node-positive disease, or metastatic disease. We also studied survival outcomes among these various subgroups of patients and explored the possible survival benefit

Full access

A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma

David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, and Henry S. Friedman

associated with poor outcome among patients with glioblastoma. 30 , 31 VEGF-A isoforms generated by alternative splicing can also originate from host sources, such as invading macrophages and platelets, whereas tumor stroma can sequester larger isoforms that

Full access

Management of Patients With Lung Cancer and Poor Performance Status

Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti

patient populations that respond differently to treatment and have different outcomes. 7 Another challenge in interpreting the trial evidence for this group of patients is the subjectivity associated with assigning a PS to any given patient. A recent

Full access

New Treatment Guidelines for Penile Cancer

Philippe E. Spiess

NCCN Panel on bladder and penile cancers. With the use of non–evidence-based treatment approaches, outcomes can widely vary. To clarify some of the controversies associated with the treatment of penile cancer, NCCN has created inaugural NCCN Clinical

Full access

Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines

Justine M. Kahn and Melissa Beauchemin

, adolescents, and young adults (AYA; aged 15–39 years) with HL exceed 95%, with event-free survival (EFS) rates >85%. 4 The treatment successes in HL are attributed, in part, to 4 key factors: (1) research to identify disease-related predictors of poor outcome

Full access

Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities

Doris Howell, Gregory R. Pond, Denise Bryant-Lukosius, Melanie Powis, Patrick T. McGowan, Tutsirai Makuwaza, Vishal Kukreti, Sara Rask, Saidah Hack, and Monika K. Krzyzanowska

also examined preliminary estimates of effectiveness based on patient-reported outcomes. Methods Participants and Recruitment Procedures Ethics approval was obtained from the Ontario Cancer Research Ethics Board for all participating sites

Full access

Infusion-Compatible Antibiotic Formulations for Rapid Administration to Improve Outcomes in Cancer Outpatients With Severe Sepsis and Septic Shock: The Sepsis STAT Pack

Jason D. Goldman, Amelia Gallaher, Rupali Jain, Zach Stednick, Manoj Menon, Michael J. Boeckh, Paul S. Pottinger, Stephen M. Schwartz, and Corey Casper

measure relative risk of (1) cumulative 30-day mortality, (2) development of SSh, or (3) the combined outcome of cumulative 30-day mortality or development of SSh. Multivariate models were constructed to control for prespecified confounding variables

Full access

Advances in the Care of Adult Patients With Acute Lymphoblastic Leukemia: Optimism Tempered by Reality

Joseph C. Alvarnas and Patrick A. Brown

Outcomes for patients with acute lymphoblastic leukemia (ALL) have improved dramatically over the past 4 decades. Overall 5-year relative survival rates for patients with ALL have increased from 40.6% during the period between 1975 and 1977 to 70